Changes to Facility. R&DCo shall not, and shall cause the other R&DCo Group Members not to, make any alterations or improvements to the Facility without the prior written consent of Ikaria, which consent shall not be unreasonably withheld, conditioned or delayed. Failure of Ikaria’s landlord to consent to or approve the alterations or improvements, where required, or non-compliance of alterations or improvements with the Lease, shall be a reasonable grounds for Ikaria to withhold consent under this Section.
Changes to Facility. Customer shall notify Company in advance of any changes to be made to Customer’s Facility having the potential of materially affecting the Kentucky Utilities System or other facilities interconnected to the Kentucky Utilities System.
Changes to Facility. Hovione will not use any facility in the Manufacture of Product other than the Facilities. Hovione will not make any change at the Facility that would result in a change of the Manufacturing Process or may affect the identity, quality, purity, potency or bioavailability of Product or that would otherwise require prior approval of any applicable Regulatory Authority without giving Client at least * days’ prior written notice of such change and making available to Client all information required for applicable Regulatory Authority approval. Hovione will notify Client, in writing, of all other changes to the Facilities as required by Applicable Law.
Changes to Facility. Acquirer shall not make any alterations or improvements to the Facility without the prior written consent of Seller.
Changes to Facility. Except as expressly permitted pursuant to Section 2.6 and this Article 4, MediWound shall not perform any change of any part of any Facility, change the physical location within the Facility for Manufacturing any Products or change the Facility at which the Manufacturing of any Products takes place, if such change would reasonably be expected to (a) impact the Regulatory Approval for one or more of the Products or any regulatory compliance program; or (b) result in inability (permanent or temporary) of MediWound to Manufacture, supply or otherwise perform its obligations per Vericel’s Rolling Forecast in accordance with this Agreement. For any change in the Facility at which the Manufacturing of any Products takes place, MediWound shall (i) give Vericel notice within the applicable Change Notification Period, and (ii) provide Vericel a plan for avoiding any interruption in supply that may result from such change. In the event of a “Major” change to the Facility (as detailed in Schedule 4.1), such change will be treated in accordance with Section 2.6(b).
Changes to Facility. In addition to changes to the facility agreement we can make in Part A, Part B, Part D or Part E, we can:
